Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Structural Insights into the Development of Cycloguanil Derivatives as Trypanosoma brucei Pteridine-Reductase-1 Inhibitors.

Landi G, Linciano P, Borsari C, Bertolacini CP, Moraes CB, Cordeiro-da-Silva A, Gul S, Witt G, Kuzikov M, Costi MP, Pozzi C, Mangani S.

ACS Infect Dis. 2019 Jul 12;5(7):1105-1114. doi: 10.1021/acsinfecdis.8b00358. Epub 2019 May 1.

PMID:
31012301
2.

X-ray Crystallography Deciphers the Activity of Broad-Spectrum Boronic Acid β-Lactamase Inhibitors.

Cendron L, Quotadamo A, Maso L, Bellio P, Montanari M, Celenza G, Venturelli A, Costi MP, Tondi D.

ACS Med Chem Lett. 2019 Mar 27;10(4):650-655. doi: 10.1021/acsmedchemlett.8b00607. eCollection 2019 Apr 11.

PMID:
30996812
3.

SAR Studies and Biological Characterization of a Chromen-4-one Derivative as an Anti-Trypanosoma brucei Agent.

Borsari C, Santarem N, Macedo S, Jiménez-Antón MD, Torrado JJ, Olías-Molero AI, Corral MJ, Tait A, Ferrari S, Costantino L, Luciani R, Ponterini G, Gul S, Kuzikov M, Ellinger B, Behrens B, Reinshagen J, Alunda JM, Cordeiro-da-Silva A, Costi MP.

ACS Med Chem Lett. 2019 Jan 29;10(4):528-533. doi: 10.1021/acsmedchemlett.8b00565. eCollection 2019 Apr 11.

PMID:
30996791
4.

Evidence of Destabilization of the Human Thymidylate Synthase (hTS) Dimeric Structure Induced by the Interface Mutation Q62R.

Pozzi C, Lopresti L, Santucci M, Costi MP, Mangani S.

Biomolecules. 2019 Apr 3;9(4). pii: E134. doi: 10.3390/biom9040134.

5.

Structural and Functional Characterization of the Human Thymidylate Synthase (hTS) Interface Variant R175C, New Perspectives for the Development of hTS Inhibitors.

Pozzi C, Ferrari S, Luciani R, Costi MP, Mangani S.

Molecules. 2019 Apr 7;24(7). pii: E1362. doi: 10.3390/molecules24071362.

6.

Structural Comparison of Enterococcus faecalis and Human Thymidylate Synthase Complexes with the Substrate dUMP and Its Analogue FdUMP Provides Hints about Enzyme Conformational Variabilities.

Pozzi C, Ferrari S, Luciani R, Tassone G, Costi MP, Mangani S.

Molecules. 2019 Mar 31;24(7). pii: E1257. doi: 10.3390/molecules24071257.

7.

Enhancement of Benzothiazoles as Pteridine Reductase-1 Inhibitors for the Treatment of Trypanosomatidic Infections.

Linciano P, Pozzi C, Iacono LD, di Pisa F, Landi G, Bonucci A, Gul S, Kuzikov M, Ellinger B, Witt G, Santarem N, Baptista C, Franco C, Moraes CB, Müller W, Wittig U, Luciani R, Sesenna A, Quotadamo A, Ferrari S, Pöhner I, Cordeiro-da-Silva A, Mangani S, Costantino L, Costi MP.

J Med Chem. 2019 Apr 25;62(8):3989-4012. doi: 10.1021/acs.jmedchem.8b02021. Epub 2019 Apr 9.

PMID:
30908048
8.

Excited-state intramolecular proton transfer in a bioactive flavonoid provides fluorescence observables for recognizing its engagement with target proteins.

Vanossi D, Caselli M, Pavesi G, Borsari C, Linciano P, Costi MP, Ponterini G.

Photochem Photobiol Sci. 2019 Mar 22. doi: 10.1039/c9pp00026g. [Epub ahead of print]

PMID:
30900698
9.

Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform.

Moraes CB, Witt G, Kuzikov M, Ellinger B, Calogeropoulou T, Prousis KC, Mangani S, Di Pisa F, Landi G, Iacono LD, Pozzi C, Freitas-Junior LH, Dos Santos Pascoalino B, Bertolacini CP, Behrens B, Keminer O, Leu J, Wolf M, Reinshagen J, Cordeiro-da-Silva A, Santarem N, Venturelli A, Wrigley S, Karunakaran D, Kebede B, Pöhner I, Müller W, Panecka-Hofman J, Wade RC, Fenske M, Clos J, Alunda JM, Corral MJ, Uliassi E, Bolognesi ML, Linciano P, Quotadamo A, Ferrari S, Santucci M, Borsari C, Costi MP, Gul S.

SLAS Discov. 2019 Mar;24(3):346-361. doi: 10.1177/2472555218823171.

10.

Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer.

Conteduca V, Gurioli G, Rossi L, Scarpi E, Lolli C, Schepisi G, Farolfi A, De Lisi D, Gallà V, Burgio SL, Menna C, Amadori A, Losi L, Amadori D, Costi MP, De Giorgi U.

BMC Cancer. 2018 Dec 19;18(1):1267. doi: 10.1186/s12885-018-5180-1.

11.

Repurposing of Drugs Targeting YAP-TEAD Functions.

Elisi GM, Santucci M, D'Arca D, Lauriola A, Marverti G, Losi L, Scalvini L, Bolognesi ML, Mor M, Costi MP.

Cancers (Basel). 2018 Sep 14;10(9). pii: E329. doi: 10.3390/cancers10090329. Review.

12.

pH-Promoted Release of a Novel Anti-Tumour Peptide by "Stealth" Liposomes: Effect of Nanocarriers on the Drug Activity in Cis-Platinum Resistant Cancer Cells.

Sacchetti F, Marverti G, D'Arca D, Severi L, Maretti E, Iannuccelli V, Pacifico S, Ponterini G, Costi MP, Leo E.

Pharm Res. 2018 Sep 12;35(11):206. doi: 10.1007/s11095-018-2489-z.

PMID:
30209680
13.

Conformational Propensity and Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate Synthase and Ovarian Cancer Cell Growth.

Saxena P, Severi L, Santucci M, Taddia L, Ferrari S, Luciani R, Marverti G, Marraccini C, Tondi D, Mor M, Scalvini L, Vitiello S, Losi L, Fonda S, Pacifico S, Guerrini R, D'Arca D, Ponterini G, Costi MP.

J Med Chem. 2018 Aug 23;61(16):7374-7380. doi: 10.1021/acs.jmedchem.7b01699. Epub 2018 Aug 13.

PMID:
30035541
14.

Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR).

Francesconi V, Giovannini L, Santucci M, Cichero E, Costi MP, Naesens L, Giordanetto F, Tonelli M.

Eur J Med Chem. 2018 Jul 15;155:229-243. doi: 10.1016/j.ejmech.2018.05.059. Epub 2018 Jun 2.

PMID:
29886325
15.

Pharmacokinetics and disposition of miltefosine in healthy mice and hamsters experimentally infected with Leishmania infantum.

Jiménez-Antón MD, García-Calvo E, Gutiérrez C, Escribano MD, Kayali N, Luque-García JL, Olías-Molero AI, Corral MJ, Costi MP, Torrado JJ, Alunda JM.

Eur J Pharm Sci. 2018 Aug 30;121:281-286. doi: 10.1016/j.ejps.2018.06.002. Epub 2018 Jun 5.

PMID:
29883726
16.

Proteomic and Bioinformatic Studies for the Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian Cancer.

Severi L, Losi L, Fonda S, Taddia L, Gozzi G, Marverti G, Magni F, Chinello C, Stella M, Sheouli J, Braicu EI, Genovese F, Lauriola A, Marraccini C, Gualandi A, D'Arca D, Ferrari S, Costi MP.

Front Pharmacol. 2018 May 8;9:454. doi: 10.3389/fphar.2018.00454. eCollection 2018.

17.

New TRAP1 and Hsp90 chaperone inhibitors with cationic components: Preliminary studies on mitochondrial targeting.

Rondanin R, Lettini G, Oliva P, Baruchello R, Costantini C, Trapella C, Simoni D, Bernardi T, Sisinni L, Pietrafesa M, Ponterini G, Costi MP, Vignudelli T, Luciani R, Matassa DS, Esposito F, Landriscina M.

Bioorg Med Chem Lett. 2018 Jul 15;28(13):2289-2293. doi: 10.1016/j.bmcl.2018.05.031. Epub 2018 May 15.

PMID:
29807796
18.

Human Thymidylate Synthase Inhibitors Halting Ovarian Cancer Growth.

Ferrari S, Severi L, Pozzi C, Quotadamo A, Ponterini G, Losi L, Marverti G, Costi MP.

Vitam Horm. 2018;107:473-513. doi: 10.1016/bs.vh.2017.12.002. Epub 2018 Feb 12. Review.

PMID:
29544641
19.

Development of a Focused Library of Triazole-Linked Privileged-Structure-Based Conjugates Leading to the Discovery of Novel Phenotypic Hits against Protozoan Parasitic Infections.

Uliassi E, Piazzi L, Belluti F, Mazzanti A, Kaiser M, Brun R, Moraes CB, Freitas-Junior LH, Gul S, Kuzikov M, Ellinger B, Borsari C, Costi MP, Bolognesi ML.

ChemMedChem. 2018 Apr 6;13(7):678-683. doi: 10.1002/cmdc.201700786. Epub 2018 Feb 16.

PMID:
29451361
20.

Aryl thiosemicarbazones for the treatment of trypanosomatidic infections.

Linciano P, Moraes CB, Alcantara LM, Franco CH, Pascoalino B, Freitas-Junior LH, Macedo S, Santarem N, Cordeiro-da-Silva A, Gul S, Witt G, Kuzikov M, Ellinger B, Ferrari S, Luciani R, Quotadamo A, Costantino L, Costi MP.

Eur J Med Chem. 2018 Feb 25;146:423-434. doi: 10.1016/j.ejmech.2018.01.043. Epub 2018 Jan 31.

PMID:
29407968
21.

Computational and biological profile of boronic acids for the detection of bacterial serine- and metallo-β-lactamases.

Santucci M, Spyrakis F, Cross S, Quotadamo A, Farina D, Tondi D, De Luca F, Docquier JD, Prieto AI, Ibacache C, Blázquez J, Venturelli A, Cruciani G, Costi MP.

Sci Rep. 2017 Dec 18;7(1):17716. doi: 10.1038/s41598-017-17399-7.

22.

In Silico Identification and In Vitro Evaluation of Natural Inhibitors of Leishmania major Pteridine Reductase I.

Herrmann FC, Sivakumar N, Jose J, Costi MP, Pozzi C, Schmidt TJ.

Molecules. 2017 Dec 6;22(12). pii: E2166. doi: 10.3390/molecules22122166.

23.

Label-free fiber optic optrode for the detection of class C β-lactamases expressed by drug resistant bacteria.

Zuppolini S, Quero G, Consales M, Diodato L, Vaiano P, Venturelli A, Santucci M, Spyrakis F, Costi MP, Giordano M, Cutolo A, Cusano A, Borriello A.

Biomed Opt Express. 2017 Oct 23;8(11):5191-5205. doi: 10.1364/BOE.8.005191. eCollection 2017 Nov 1.

24.

Crassiflorone derivatives that inhibit Trypanosoma brucei glyceraldehyde-3-phosphate dehydrogenase (TbGAPDH) and Trypanosoma cruzi trypanothione reductase (TcTR) and display trypanocidal activity.

Uliassi E, Fiorani G, Krauth-Siegel RL, Bergamini C, Fato R, Bianchini G, Carlos Menéndez J, Molina MT, López-Montero E, Falchi F, Cavalli A, Gul S, Kuzikov M, Ellinger B, Witt G, Moraes CB, Freitas-Junior LH, Borsari C, Costi MP, Bolognesi ML.

Eur J Med Chem. 2017 Dec 1;141:138-148. doi: 10.1016/j.ejmech.2017.10.005. Epub 2017 Oct 3.

PMID:
29031061
25.

Exploiting the 2-Amino-1,3,4-thiadiazole Scaffold To Inhibit Trypanosoma brucei Pteridine Reductase in Support of Early-Stage Drug Discovery.

Linciano P, Dawson A, Pöhner I, Costa DM, Sá MS, Cordeiro-da-Silva A, Luciani R, Gul S, Witt G, Ellinger B, Kuzikov M, Gribbon P, Reinshagen J, Wolf M, Behrens B, Hannaert V, Michels PAM, Nerini E, Pozzi C, di Pisa F, Landi G, Santarem N, Ferrari S, Saxena P, Lazzari S, Cannazza G, Freitas-Junior LH, Moraes CB, Pascoalino BS, Alcântara LM, Bertolacini CP, Fontana V, Wittig U, Müller W, Wade RC, Hunter WN, Mangani S, Costantino L, Costi MP.

ACS Omega. 2017 Sep 30;2(9):5666-5683. doi: 10.1021/acsomega.7b00473. Epub 2017 Sep 11.

26.

Comparative mapping of on-targets and off-targets for the discovery of anti-trypanosomatid folate pathway inhibitors.

Panecka-Hofman J, Pöhner I, Spyrakis F, Zeppelin T, Di Pisa F, Dello Iacono L, Bonucci A, Quotadamo A, Venturelli A, Mangani S, Costi MP, Wade RC.

Biochim Biophys Acta Gen Subj. 2017 Dec;1861(12):3215-3230. doi: 10.1016/j.bbagen.2017.09.012. Epub 2017 Sep 20.

PMID:
28939533
27.

TRAP1: a viable therapeutic target for future cancer treatments?

Lettini G, Maddalena F, Sisinni L, Condelli V, Matassa DS, Costi MP, Simoni D, Esposito F, Landriscina M.

Expert Opin Ther Targets. 2017 Aug;21(8):805-815. doi: 10.1080/14728222.2017.1349755. Epub 2017 Jul 18. Review.

PMID:
28664757
28.

The Future of Drug Development for Neglected Tropical Diseases: How the European Commission Can Continue to Make a Difference.

Pierce RJ, MacDougall J, Leurs R, Costi MP.

Trends Parasitol. 2017 Aug;33(8):581-583. doi: 10.1016/j.pt.2017.04.007. Epub 2017 May 18.

PMID:
28529130
29.

Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.

Tonelli M, Naesens L, Gazzarrini S, Santucci M, Cichero E, Tasso B, Moroni A, Costi MP, Loddo R.

Eur J Med Chem. 2017 Jul 28;135:467-478. doi: 10.1016/j.ejmech.2017.04.070. Epub 2017 Apr 27.

PMID:
28477572
30.

Chroman-4-One Derivatives Targeting Pteridine Reductase 1 and Showing Anti-Parasitic Activity.

Di Pisa F, Landi G, Dello Iacono L, Pozzi C, Borsari C, Ferrari S, Santucci M, Santarem N, Cordeiro-da-Silva A, Moraes CB, Alcantara LM, Fontana V, Freitas-Junior LH, Gul S, Kuzikov M, Behrens B, Pöhner I, Wade RC, Costi MP, Mangani S.

Molecules. 2017 Mar 8;22(3). pii: E426. doi: 10.3390/molecules22030426.

31.

Molecular basis for covalent inhibition of glyceraldehyde-3-phosphate dehydrogenase by a 2-phenoxy-1,4-naphthoquinone small molecule.

Bruno S, Uliassi E, Zaffagnini M, Prati F, Bergamini C, Amorati R, Paredi G, Margiotta M, Conti P, Costi MP, Kaiser M, Cavalli A, Fato R, Bolognesi ML.

Chem Biol Drug Des. 2017 Aug;90(2):225-235. doi: 10.1111/cbdd.12941. Epub 2017 Mar 6.

32.

Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.

Borsari C, Santarem N, Torrado J, Olías AI, Corral MJ, Baptista C, Gul S, Wolf M, Kuzikov M, Ellinger B, Witt G, Gribbon P, Reinshagen J, Linciano P, Tait A, Costantino L, Freitas-Junior LH, Moraes CB, Bruno Dos Santos P, Alcântara LM, Franco CH, Bertolacini CD, Fontana V, Tejera Nevado P, Clos J, Alunda JM, Cordeiro-da-Silva A, Ferrari S, Costi MP.

Eur J Med Chem. 2017 Jan 27;126:1129-1135. doi: 10.1016/j.ejmech.2016.12.017. Epub 2016 Dec 9.

PMID:
28064141
33.

Target-based approaches for the discovery of new antimycobacterial drugs.

Borsari C, Ferrari S, Venturelli A, Costi MP.

Drug Discov Today. 2017 Mar;22(3):576-584. doi: 10.1016/j.drudis.2016.11.014. Epub 2016 Nov 23. Review.

PMID:
27890671
34.

Conveying a newly designed hydrophilic anti-human thymidylate synthase peptide to cisplatin resistant cancer cells: are pH-sensitive liposomes more effective than conventional ones?

Sacchetti F, D'Arca D, Genovese F, Pacifico S, Maretti E, Hanuskova M, Iannuccelli V, Costi MP, Leo E.

Drug Dev Ind Pharm. 2017 Mar;43(3):465-473. doi: 10.1080/03639045.2016.1262870. Epub 2016 Dec 26.

PMID:
27885848
35.

Correction to "Mass Spectrometric/Bioinformatic Identification of a Protein Subset That Characterizes the Cellular Activity of Anticancer Peptides".

Genovese F, Gualandi A, Taddia L, Marverti G, Pirondi S, Marraccini C, Perco P, Pelà M, Guerrini R, Amoroso MR, Esposito F, Martello A, Ponterini G, D'Arca D, Costi MP.

J Proteome Res. 2016 Oct 7;15(10):3944. Epub 2016 Sep 23. No abstract available.

PMID:
27662068
36.

Virtual Screening and X-ray Crystallography Identify Non-Substrate Analog Inhibitors of Flavin-Dependent Thymidylate Synthase.

Luciani R, Saxena P, Surade S, Santucci M, Venturelli A, Borsari C, Marverti G, Ponterini G, Ferrari S, Blundell TL, Costi MP.

J Med Chem. 2016 Oct 13;59(19):9269-9275. Epub 2016 Sep 29.

PMID:
27589670
37.

Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.

Borsari C, Luciani R, Pozzi C, Poehner I, Henrich S, Trande M, Cordeiro-da-Silva A, Santarem N, Baptista C, Tait A, Di Pisa F, Dello Iacono L, Landi G, Gul S, Wolf M, Kuzikov M, Ellinger B, Reinshagen J, Witt G, Gribbon P, Kohler M, Keminer O, Behrens B, Costantino L, Tejera Nevado P, Bifeld E, Eick J, Clos J, Torrado J, Jiménez-Antón MD, Corral MJ, Alunda JM, Pellati F, Wade RC, Ferrari S, Mangani S, Costi MP.

J Med Chem. 2016 Aug 25;59(16):7598-616. doi: 10.1021/acs.jmedchem.6b00698. Epub 2016 Aug 5.

PMID:
27411733
38.

Comparing Drug Images and Repurposing Drugs with BioGPS and FLAPdock: The Thymidylate Synthase Case.

Siragusa L, Luciani R, Borsari C, Ferrari S, Costi MP, Cruciani G, Spyrakis F.

ChemMedChem. 2016 Aug 5;11(15):1653-66. doi: 10.1002/cmdc.201600121. Epub 2016 Jul 12.

39.

Intracellular quantitative detection of human thymidylate synthase engagement with an unconventional inhibitor using tetracysteine-diarsenical-probe technology.

Ponterini G, Martello A, Pavesi G, Lauriola A, Luciani R, Santucci M, Pelà M, Gozzi G, Pacifico S, Guerrini R, Marverti G, Costi MP, D'Arca D.

Sci Rep. 2016 Jun 2;6:27198. doi: 10.1038/srep27198.

40.

Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.

Taddia L, D'Arca D, Ferrari S, Marraccini C, Severi L, Ponterini G, Assaraf YG, Marverti G, Costi MP.

Drug Resist Updat. 2015 Nov;23:20-54. doi: 10.1016/j.drup.2015.10.003. Epub 2015 Oct 31. Review.

PMID:
26690339
41.

Current and Future Chemotherapy for Chagas Disease.

Gaspar L, Moraes CB, Freitas-Junior LH, Ferrari S, Costantino L, Costi MP, Coron RP, Smith TK, Siqueira-Neto JL, McKerrow JH, Cordeiro-da-Silva A.

Curr Med Chem. 2015;22(37):4293-312. Review.

PMID:
26477622
42.

Enhanced anti-hyperproliferative activity of human thymidylate synthase inhibitor peptide by solid lipid nanoparticle delivery.

Sacchetti F, Marraccini C, D'Arca D, Pelà M, Pinetti D, Maretti E, Hanuskova M, Iannuccelli V, Costi MP, Leo E.

Colloids Surf B Biointerfaces. 2015 Dec 1;136:346-54. doi: 10.1016/j.colsurfb.2015.09.040. Epub 2015 Sep 25.

PMID:
26433347
43.

Decoding the Structural Basis For Carbapenem Hydrolysis By Class A β-lactamases: Fishing For A Pharmacophore.

Tondi D, Cross S, Venturelli A, Costi MP, Cruciani G, Spyrakis F.

Curr Drug Targets. 2016;17(9):983-1005. Review.

PMID:
26424401
44.

Characterization of 2,4-Diamino-6-oxo-1,6-dihydropyrimidin-5-yl Ureido Based Inhibitors of Trypanosoma brucei FolD and Testing for Antiparasitic Activity.

Eadsforth TC, Pinto A, Luciani R, Tamborini L, Cullia G, De Micheli C, Marinelli L, Cosconati S, Novellino E, Lo Presti L, Cordeiro da Silva A, Conti P, Hunter WN, Costi MP.

J Med Chem. 2015 Oct 22;58(20):7938-48. doi: 10.1021/acs.jmedchem.5b00687. Epub 2015 Sep 16.

45.

Hotspots in an obligate homodimeric anticancer target. Structural and functional effects of interfacial mutations in human thymidylate synthase.

Salo-Ahen OM, Tochowicz A, Pozzi C, Cardinale D, Ferrari S, Boum Y, Mangani S, Stroud RM, Saxena P, Myllykallio H, Costi MP, Ponterini G, Wade RC.

J Med Chem. 2015 Apr 23;58(8):3572-81. doi: 10.1021/acs.jmedchem.5b00137. Epub 2015 Apr 1.

46.

The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment.

Santucci M, Vignudelli T, Ferrari S, Mor M, Scalvini L, Bolognesi ML, Uliassi E, Costi MP.

J Med Chem. 2015 Jun 25;58(12):4857-73. doi: 10.1021/jm501615v. Epub 2015 Mar 11. Review.

PMID:
25719868
47.

2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1.

Neres J, Hartkoorn RC, Chiarelli LR, Gadupudi R, Pasca MR, Mori G, Venturelli A, Savina S, Makarov V, Kolly GS, Molteni E, Binda C, Dhar N, Ferrari S, Brodin P, Delorme V, Landry V, de Jesus Lopes Ribeiro AL, Farina D, Saxena P, Pojer F, Carta A, Luciani R, Porta A, Zanoni G, De Rossi E, Costi MP, Riccardi G, Cole ST.

ACS Chem Biol. 2015 Mar 20;10(3):705-14. doi: 10.1021/cb5007163. Epub 2014 Dec 9.

PMID:
25427196
48.

Alanine mutants of the interface residues of human thymidylate synthase decode key features of the binding mode of allosteric anticancer peptides.

Tochowicz A, Santucci M, Saxena P, Guaitoli G, Trande M, Finer-Moore J, Stroud RM, Costi MP.

J Med Chem. 2015 Jan 22;58(2):1012-8. doi: 10.1021/jm5011176. Epub 2014 Dec 29.

PMID:
25427005
49.

Internalization and stability of a thymidylate synthase Peptide inhibitor in ovarian cancer cells.

Cannazza G, Cazzato AS, Marraccini C, Pavesi G, Pirondi S, Guerrini R, Pelà M, Frassineti C, Ferrari S, Marverti G, Ponterini G, Costi MP.

J Med Chem. 2014 Dec 26;57(24):10551-6. doi: 10.1021/jm501397h. Epub 2014 Dec 3.

PMID:
25353379
50.

Mass spectrometric/bioinformatic identification of a protein subset that characterizes the cellular activity of anticancer peptides.

Genovese F, Gualandi A, Taddia L, Marverti G, Pirondi S, Marraccini C, Perco P, Pelà M, Guerrini R, Amoroso MR, Esposito F, Martello A, Ponterini G, D'Arca D, Costi MP.

J Proteome Res. 2014 Nov 7;13(11):5250-61. doi: 10.1021/pr500510v. Epub 2014 Sep 29. Erratum in: J Proteome Res. 2016 Oct 7;15(10 ):3944.

PMID:
25196676

Supplemental Content

Loading ...
Support Center